Cargando…
Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)
BACKGROUND AND AIM: Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan. DESIGN: Randomized, double-blind, placebo-controlled, one-year intervention trial. SETTING...
Autores principales: | Peters, Christian Daugaard, Kjaergaard, Krista Dybtved, Jensen, Jens Dam, Christensen, Kent Lodberg, Strandhave, Charlotte, Tietze, Ida Noerager, Novosel, Marija Kristina, Bibby, Bo Martin, Jespersen, Bente |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452642/ https://www.ncbi.nlm.nih.gov/pubmed/26030651 http://dx.doi.org/10.1371/journal.pone.0126882 |
Ejemplares similares
-
Preserving residual renal function in dialysis patients: an update on evidence to assist clinical decision making
por: Kjaergaard, Krista Dybtved, et al.
Publicado: (2011) -
NEMA characterization of the SAFIR prototype PET insert
por: Khateri, Parisa, et al.
Publicado: (2022) -
High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome
por: Peters, Christian D., et al.
Publicado: (2020) -
Changes of Hemodynamic Parameters after Intradialytic Glucose Injection
por: Niemczyk, Longin, et al.
Publicado: (2023) -
Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial
por: Levy-Schousboe, Karin, et al.
Publicado: (2021)